BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 36982721)

  • 21. Cabozantinib for the treatment of kidney cancer.
    Abdelaziz A; Vaishampayan U
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):577-584. PubMed ID: 28633552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
    Choueiri TK; Escudier B; Powles T; Tannir NM; Mainwaring PN; Rini BI; Hammers HJ; Donskov F; Roth BJ; Peltola K; Lee JL; Heng DYC; Schmidinger M; Agarwal N; Sternberg CN; McDermott DF; Aftab DT; Hessel C; Scheffold C; Schwab G; Hutson TE; Pal S; Motzer RJ;
    Lancet Oncol; 2016 Jul; 17(7):917-927. PubMed ID: 27279544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors.
    Tahiri A; Puco K; Naji F; Kristensen VN; Alfsen GC; Farkas L; Nilsen FS; Müller S; Oldenburg J; Geisler J
    Oncotarget; 2022; 13():970-981. PubMed ID: 36093296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy.
    Grassi P; Verzoni E; Ratta R; Mennitto A; de Braud F; Procopio G
    Drug Des Devel Ther; 2016; 10():2167-72. PubMed ID: 27462141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
    Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
    Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.
    Tannir NM; Schwab G; Grünwald V
    Curr Oncol Rep; 2017 Feb; 19(2):14. PubMed ID: 28247252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
    Cella D; Motzer RJ; Suarez C; Blum SI; Ejzykowicz F; Hamilton M; Wallace JF; Simsek B; Zhang J; Ivanescu C; Apolo AB; Choueiri TK
    Lancet Oncol; 2022 Feb; 23(2):292-303. PubMed ID: 35032437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of axitinib versus sunitinib as first-line therapy to patients with metastatic renal cell carcinoma in the immune-oncology era.
    Numakura K; Muto Y; Naito S; Hatakeyama S; Kato R; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Arai Y; Ito A; Nishiyama H; Kojima Y; Obara W; Ohyama C; Tsuchiya N; Habuchi T
    Cancer Med; 2021 Sep; 10(17):5839-5846. PubMed ID: 34313025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
    Abdelaziz A; Vaishampayan U
    Curr Treat Options Oncol; 2017 Mar; 18(3):18. PubMed ID: 28286925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21).
    Mennitto A; Zattarin E; Di Maio M; Bimbatti D; De Giorgi U; Buti S; Santini D; Casadei C; Sorarù M; Messina C; Mucciarini C; Di Lorenzo G; Roviello G; Buttigliero C; Stellato M; Sepe P; Claps M; Guadalupi V; Ottini A; Pignata S; De Braud FG; Verzoni E; Procopio G
    Expert Rev Anticancer Ther; 2022 Jan; 22(1):115-121. PubMed ID: 34738499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Gan CL; Dudani S; Wells JC; Donskov F; Pal SK; Dizman N; Rathi N; Beuselinck B; Yan F; Lalani AA; Hansen A; Szabados B; de Velasco G; Tran B; Lee JL; Vaishampayan UN; Bjarnason GA; Subasri M; Choueiri TK; Heng DYC
    Cancer Med; 2021 Feb; 10(4):1212-1221. PubMed ID: 33463028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response to cabozantinib in renal cell carcinoma with cardiac metastases.
    Stellato M; Cursano MC; Citarella F; Pantano F; Russano M; Dell' Aquila E; Vincenzi B; Tonini G; Santini D
    Anticancer Drugs; 2020 Mar; 31(3):314-318. PubMed ID: 31929349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Interdisciplinary Recommendations for the Treatment of Metastatic Renal Cell Carcinoma].
    Miller K; Bergmann L; Doehn C; Gschwend J; Keilholz U
    Aktuelle Urol; 2017 Feb; 48(1):72-78. PubMed ID: 28403496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
    Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K
    Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.
    Escudier B; Powles T; Motzer RJ; Olencki T; Arén Frontera O; Oudard S; Rolland F; Tomczak P; Castellano D; Appleman LJ; Drabkin H; Vaena D; Milwee S; Youkstetter J; Lougheed JC; Bracarda S; Choueiri TK
    J Clin Oncol; 2018 Mar; 36(8):765-772. PubMed ID: 29309249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China.
    Wang H; Wang Y; Li L; Zhou H; Lili S; Li L; Yike S; Aixia M
    Front Public Health; 2022; 10():954264. PubMed ID: 36159269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gas6-Axl signaling in presence of Sunitinib is enhanced, diversified and sustained in renal tumor cells, resulting in tumor-progressive advantages.
    Gustafsson A; Fritz HKM; Dahlbäck B
    Exp Cell Res; 2017 Jun; 355(1):47-56. PubMed ID: 28327411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.
    Zhao H; Nolley R; Chan AMW; Rankin EB; Peehl DM
    Cancer Biol Ther; 2017 Nov; 18(11):863-871. PubMed ID: 27715452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
    Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
    J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma.
    Wu Y; Chen S; Yang X; Sato K; Lal P; Wang Y; Shinkle AT; Wendl MC; Primeau TM; Zhao Y; Gould A; Sun H; Mudd JL; Hoog J; Mashl RJ; Wyczalkowski MA; Mo CK; Liu R; Herndon JM; Davies SR; Liu D; Ding X; Evrard YA; Welm BE; Lum D; Koh MY; Welm AL; Chuang JH; Moscow JA; Meric-Bernstam F; Govindan R; Li S; Hsieh J; Fields RC; Lim KH; Ma CX; Zhang H; Ding L; Chen F
    Cancer Res; 2023 Dec; 83(24):4161-4178. PubMed ID: 38098449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.